Oyster_Point_RegisteredTM_Logo_RGB.jpg
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
August 17, 2022 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
SightSciences_Logo_2C_RGB.png
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
August 16, 2022 08:01 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
ocugen_4C_LOGO (002).png
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 12, 2022 07:30 ET | Ocugen
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
logo color s and clearside.jpg
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 07:05 ET | Clearside Biomedical, Inc.
- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - ...
Oyster_Point_RegisteredTM_Logo_RGB.jpg
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
August 08, 2022 16:03 ET | Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...
tarsus-logo-stacked-color-532x626.png
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 05, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
logo color s and clearside.jpg
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
August 03, 2022 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022
July 27, 2022 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
July 26, 2022 07:05 ET | Clearside Biomedical, Inc.
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a...
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
July 26, 2022 06:15 ET | RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the...